Starting with high quality reagents is one good way to futureproof cell therapy programs. Here we examine when and how to transition to GMP critical reagents.

Cell therapy developers face many challenges as they transition from benchtop to bedside. Utilizing high quality grade reagents and clinic-ready processes earlier in the development pipeline is one good way to futureproof cell therapy development and manufacturing programs. Here we examine when and how to consider transitioning from research-use only to animal free (AF) and GMP critical reagents, covering key topics including:

• The top five reasons to start with high quality animal free reagents before IND filings.
• How to navigate unclear guidance on ancillary cell therapy reagents
• Advice on how to balance reagent costs and benefits
• Tips for avoiding costly supply disruptions that can delay programs